BioCryst Pharma (BCRX) Tops Q1 EPS by 7c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.74 +0.62%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
SQZB, ARDS, MDRX, More
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
SQZB, ARDS, MDRX, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of $0.00, $0.07 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $134.2 million versus the consensus estimate of $127.91 million.
GUIDANCE:
BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $563.6 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic Expected to Tell Investors It Sees a More Than $30T Total Addressable Market - WSJ
- Morgan Stanley Downgrades Nichirei Corp (2871:JP) to Equalweight
- Deutsche Bank sees Walmart's international growth strategy expanding
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
